FDG PET of the Salivary Glands
DOWNLOAD FACT SHEET IN PDF

References:

1) Goerres GW, von Schulthess GK, Hany TF. Positron Emission Tomography and PET CT of the
Head and Neck: FDG Uptake in Normal Anatomy, in Benign Lesions, and in Changes Resulting
from Treatment. AJR 2002;179:1337-1343 [PDF]

2) Blodgett TM, Fukui MB, Snyderman CH. Combined PET-CT in the Head and Neck: Part 1.
Physiologic, Altered Physiologic, and Artifactual FDG Uptake. Radiographics 2005;25:897-912
[PDF]

3) Shammas A, Lim R, Charron M. Pediatric FDG PET/CT: Physiologic Uptake, Normal Variants,
and Benign Conditions. Radiographics 2009;29:1467-1486 [PDF]

4) Bhargava P, Rahman S, Wendt J. Atlas of Confounding Factors in Head and Neck PET/CT
Imaging. Clin Nucl Med 2011;36:e20-e29 [PDF]

5) Burrell SC, Van den Abbeele AD. 2-Deoxy-2-[F-18]fluoro-D-glucose-Positron Emission
Tomography of the Head and Neck: An Atlas of Normal Uptake and Variants. Mol Imaging Biol
2005;7:244-256 [PDF]

6) Kapoor V, Fukui MB, McCook BM. Role of 18F-FDG PET/CT in the Treatment of Head and Neck
Cancers: Principles, Technique, Normal Distribution, and Initial Staging. AJR 2005;184:579-587
[PDF]

7) Nakamoto Y, Tatsumi M, Hammoud D. Normal FDG Distribution Patterns in the Head and
Neck: PET/CT Evaluation. Radiology 2005;234:879-885 [PDF]

8) Keyes JW, Harkness BA, Greven KM. Salivary Gland Tumors: Pretherapy Evaluation with PET.
Radiology 1994;192:99-102 [PDF]

9) Uchida Y, Minoshima S, Kawata T. Diagnostic Value of FDG PET and Salivary Gland
Scintigraphy for Parotid Tumors. Clin Nucl Med 2005;30(3):170-176 [PDF]

10) Okamura T, Kawabe J, Koyama K. Fluorine-18 Fluorodeoxyglucose Positron Emission
Tomography Imaging of Parotid Mass Lesions. Acta Otolarynol Suppl 1998;538:209-213 [PDF]

11) McGuirt WF, Keyes JW Jr, Greven KM. Preoperative identification of benign versus malignant
parotid masses: a comparative study including positron emission tomography. Laryngoscope
1995;105:579-584 [PDF]

12) Horiuchi M, Yasuda S, Shohtsu A. Four cases of Warthin's tumor of the parotid gland
detected with FDG PET. Annals of Nuclear Medicine 1998;12(1):47-50 [PDF]

13) Shah VN, Branstetter IV BF. Oncocytoma of the Parotid Gland: A Potential False-Positive
Finding on 18F-FDG PET. AJR 2007;189:W212-214 [PDF]

14) Basu S, Houseni M, Alavi A. Significance of incidental fluorodeoxyglucose uptake in the
parotid glands and its impact on patient management. Nucl Med Commun 2008;29:367-373 [PDF]

15) Jadvar H, Bonyadlou S, Iagaru A. FDG PET-CT Demonstration of Sjogren's Sialoadenitis. Clin
Nucl Med 2005;30(1):698-699 [PDF]

16) Roh JL, Ryu CH, Choi SH. Clinical Utility of 18F-FDG PET for Patients with Salivary Gland
Malignancies. J Nucl Med 2007;48:240-246 [PDF]

17) Wang HC, Zuo CT, Hua FC. Efficacy of conventional whole-body 18F-FDG PET/CT in the
incidental findings of parotid masses. Ann Nucl Med 2010;24:571-577 [PDF]

18) Osman MM, Varvares MA, Nguyen NC. Pictorial Essay: Nonmalignant FDG Uptake in the
Head and Neck Regions. PET Clin 2007;2(4):445-468 [PDF]

 19) Hadiprodjo D, Ryan T, Troung MT. Parotid Gland Tumors: Preliminary Data for the Value of
FDG PET/CT Diagnostic Parameters. AJR 2012;198:W185-W190 [PDF]